Want to see IN:BALAXI full AI Analyst Report?
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹47.87
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.24B
Enterprise Value₹2.53K
Total Cash (Recent Filing)₹145.59M
Total Debt (Recent Filing)₹576.49M
Price to Earnings (P/E)50.1
Beta1.07
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.34
Price to Sales (P/S)0.31
P/FCF Ratio-1.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage gives Balaxi a relatively manageable debt burden and preserves financial flexibility compared with a highly indebted balance sheet, although rising debt still warrants monitoring.
Solid Gross MarginThe retained gross margin indicates that Balaxi’s marketed pharmaceutical portfolio still generates meaningful product-level economics, providing a foundation for recovery if operating costs and execution improve.
Prior Revenue GrowthThe strong FY2025 revenue increase demonstrates that Balaxi has previously been able to expand its commercial scale and product sales, supporting the potential for renewed growth despite the subsequent setback.
Bears Say
Recurring Cash BurnSustained negative operating and free cash flow shows weak earnings-to-cash conversion and raises funding risk. If persistent, cash consumption could constrain inventory, distribution investment and business expansion.
Sharp Margin DeteriorationThe steep margin contraction materially reduces earnings resilience and suggests cost or operating pressures below gross profit. A prolonged decline would weaken reinvestment capacity and returns across the business.
Low Return On EquityVery low ROE indicates that Balaxi is currently generating limited profit from its equity base. This signals inefficient capital deployment and makes balance-sheet expansion less valuable unless profitability recovers.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹47.87 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.24B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Oct 30, 2026 which is in 61 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Balaxi Pharmaceuticals Limited released its earnings results on Aug 05, 2026. The company reported ₹0.235 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Balaxi Pharmaceuticals Limited reported an EPS of ₹0.235 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.583%.
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated in Hyderabad, Telangana. Its extensive product range features pharmaceutical formulations, a variety of food products, and construction-related hardware. Notably, both its pharmaceutical and builders' hardware offerings are manufactured under contract at different plants located across India. Within its food segment, the firm markets a selection of food and biscuit products under the recognizable brand name YAP. Balaxi Global DMCC is among the key subsidiaries within the company's structure.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Par Drugs and Chemicals Limited
―
Natural Capsules Limited
―
Bilcare Ltd
―